Seroconversion following killed polio vaccine in neonates

Area of Science:

• Pediatrics
• Immunology
• Vaccinology

Background:

• Poliomyelitis remains a global health concern, necessitating effective vaccination strategies.
• The conventional oral poliovirus vaccine (OPV) schedule has limitations in achieving rapid seroconversion.
• Evaluating inactivated poliovirus vaccine (IPV) efficacy in neonates is crucial for optimizing immunization programs.

Purpose of the Study:

• To assess the efficacy of IPV in neonates.
• To determine the additive effect of IPV or OPV administered at birth on seroconversion rates.
• To compare seroconversion rates between different IPV and OPV vaccination schedules.

Main Methods:

• Neonates received either IPV or OPV at birth, followed by three doses of OPV.
• A control group received only three doses of OPV.
• Seroconversion rates against poliovirus types were measured at specific intervals.

Main Results:

• Addition of IPV or OPV at birth significantly increased seroconversion rates compared to the control group.
• Three doses of IPV initiated at birth demonstrated superior seroconversion rates versus the control.
• Higher seroconversion rates against poliovirus type III were observed in neonates receiving three doses of IPV.
• Early immunization at birth (IPV or OPV) provided significantly better protection by 6 weeks of age.

Conclusions:

• Seroconversion rates following three doses of IPV are satisfactory.
• Administering IPV or OPV at birth enhances seroconversion rates in infants.
• Initiating immunization at birth is recommended for early protection against poliomyelitis.